JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

Search

Supernus Pharmaceuticals Inc

Închisă

SectorSănătate

33.43 -0.03

Rezumat

Modificarea prețului

24h

Curent

Minim

32.9

Maxim

33.49

Indicatori cheie

By Trading Economics

Venit

-27M

-12M

Vânzări

-24M

150M

P/E

Medie Sector

29.937

38.156

Marjă de profit

-7.894

Angajați

674

EBITDA

-27M

18M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+22.72% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-292M

1.9B

Deschiderea anterioară

33.46

Închiderea anterioară

33.43

Sentimentul știrilor

By Acuity

64%

36%

339 / 375 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Supernus Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

28 iul. 2025, 21:15 UTC

Câștiguri

Waste Management 2Q Profit and Sales Rise, Cuts Fiscal Year Sales Outlook

28 iul. 2025, 23:48 UTC

Achiziții, Fuziuni, Preluări

Berkshire Hathaway Selling Part of Verisign Stake; Stock Falling After-Hours -- Barrons.com

28 iul. 2025, 23:46 UTC

Market Talk

Nikkei May Trade in Range Amid Uncertainty over Earnings -- Market Talk

28 iul. 2025, 23:42 UTC

Câștiguri

Keppel Pacific Oak US REIT: Property Expenses Rose on Year >CMOU.SG

28 iul. 2025, 23:42 UTC

Market Talk

Gold Consolidates; Trade-Deal Hopes May Weigh -- Market Talk

28 iul. 2025, 23:41 UTC

Câștiguri

Keppel Pacific Oak US REIT 1H Income Available for Distribution $19.9M Vs. $23.8M >CMOU.SG

28 iul. 2025, 23:40 UTC

Câștiguri

Keppel Pacific Oak US REIT 1H Net Property Income $40.7M Vs. $42.0M >CMOU.SG

28 iul. 2025, 23:40 UTC

Câștiguri

Keppel Pacific Oak US REIT 1H Gross Rev $74.6M Vs. $74.4M >CMOU.SG

28 iul. 2025, 23:36 UTC

Achiziții, Fuziuni, Preluări

Woodside: Development Wells in Bass Strait Could Deliver Up to 200 PJ of Gas for Sale

28 iul. 2025, 23:36 UTC

Achiziții, Fuziuni, Preluări

Woodside Identifies 4 Potential Development Wells in Bass Strait

28 iul. 2025, 23:35 UTC

Achiziții, Fuziuni, Preluări

Woodside Expects More Than US$60 Million of Savings From Bass Strait Operatorship

28 iul. 2025, 23:34 UTC

Achiziții, Fuziuni, Preluări

Woodside to Pursue Strategy that Targets Further Output, Reliability Improvements in Bass Strait

28 iul. 2025, 23:34 UTC

Achiziții, Fuziuni, Preluări

Woodside to Have Responsibility for Asset Planning, Execution Activities

28 iul. 2025, 23:33 UTC

Achiziții, Fuziuni, Preluări

Woodside, Exxon Mobil's Equity Interests in Bass Strait Assets Unchanged

28 iul. 2025, 23:32 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy Expects to Complete Deal With Exxon Mobil in 2026

28 iul. 2025, 23:32 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy Agrees to Become Operator of Bass Strait Assets

28 iul. 2025, 22:46 UTC

Market Talk

AIC Mines Bull Surprised by Capex Growth -- Market Talk

28 iul. 2025, 22:29 UTC

Câștiguri

Sandfire Resources to Provide FY26 Cost Guidance Alongside FY Results

28 iul. 2025, 22:28 UTC

Câștiguri

Sandfire Resources Expects FY26 Copper Eq Output of 149,000-165,000 Tons

28 iul. 2025, 22:27 UTC

Câștiguri

Sandfire Resources Net Debt US$123 Million at June 30

28 iul. 2025, 22:27 UTC

Câștiguri

Sandfire Resources FY Unaudited Underlying Ebitda US$528 Million

28 iul. 2025, 22:26 UTC

Câștiguri

Sandfire Resources FY Unaudited Sales Revenue US$1.18 Billion

28 iul. 2025, 22:26 UTC

Câștiguri

Sandfire Resources FY Motheo Underlying Operating Unit Cost US$40/Ton

28 iul. 2025, 22:25 UTC

Câștiguri

Sandfire Resources FY Matsa Underlying Operating Unit Cost US$78/Ton

28 iul. 2025, 22:24 UTC

Câștiguri

Sandfire Resources FY Copper Eq Output 152,400 Tons, Up 12% On-Year

28 iul. 2025, 21:35 UTC

Câștiguri

Lululemon Stock Has Rebounded. What to Expect From Earnings. -- Barrons.com

28 iul. 2025, 21:18 UTC

Achiziții, Fuziuni, Preluări

LVMH-Backed L Catterton Strikes $200 Million Deal for L.A.B. Golf, Sources Say -- WSJ

28 iul. 2025, 21:18 UTC

Achiziții, Fuziuni, Preluări

LVMH-Backed L Catterton to Buy Majority Stake After L.A.B. Golf's Putter Used to Win U.S. Open, Sources Say -- WSJ

28 iul. 2025, 21:18 UTC

Achiziții, Fuziuni, Preluări

Private-Equity Firm L Catterton Strikes $200 Million Deal for L.A.B. Golf, Sources Say -- WSJ

28 iul. 2025, 21:00 UTC

Câștiguri

Waste Management 2Q Profit and Sales Rise, Cuts FY Sales Outlook

Comparație

Modificare preț

Supernus Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

22.72% sus

Prognoză pe 12 luni

Medie 41 USD  22.72%

Maxim 45 USD

Minim 36 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSupernus Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

2

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

31.35 / 32.36Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

339 / 375 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.